Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed N/A to $27.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $27.6 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $27.6 million at Crescent Biopharma, up from $13.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $64.5 million in Q1 2025, with the low at $13.9 million in Q2 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $51.5 million, with a median of $52.4 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 22.65% in 2023, then crashed 78.46% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $51.5 million in 2021, then grew by 2.1% to $52.5 million in 2022, then increased by 20.58% to $63.3 million in 2023, then grew by 1.79% to $64.5 million in 2024, then crashed by 57.26% to $27.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $27.6 million, $13.9 million, and $13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.